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Background and aims: Cancer chemotherapy is commonly accompanied by mucositis, 
anorexia, weight loss, and anxiety independently from cancer-induced anorexia–cachexia, 
further aggravating clinical outcome. Ghrelin is a peptide hormone produced in gastric 
mucosa that reaches the brain to stimulate appetite. In plasma, ghrelin is protected from deg-
radation by ghrelin-reactive immunoglobulins (Ig). To analyze possible involvement of ghrelin 
in the chemotherapy-induced anorexia and anxiety, gastric ghrelin expression, plasma levels 
of ghrelin, and ghrelin-reactive IgG were studied in rats treated with methotrexate (MTX).
Methods: Rats received MTX (2.5 mg/kg, subcutaneously) for three consecutive days 
and were killed 3 days later, at the peak of anorexia and weight loss. Control rats received 
phosphate-buffered saline. Preproghrelin mRNA expression in the stomach was analyzed 
by in situ hybridization. Plasma levels of ghrelin and ghrelin-reactive IgG were measured 
by immunoenzymatic assays and IgG affinity kinetics by surface plasmon resonance. 
Anxiety- and depression-like behaviors in MTX-treated anorectic and in control rats were 
evaluated in the elevated plus-maze and the forced-swim test, respectively.
results: In MTX-treated anorectic rats, the number of preproghrelin mRNA-producing 
cells was found increased (by 51.3%, p < 0.001) as well were plasma concentrations of 
both ghrelin and des-acyl-ghrelin (by 70.4%, p < 0.05 and 98.3%, p < 0.01, respectively). 
In contrast, plasma levels of total IgG reactive with ghrelin and des-acyl-ghrelin were 
drastically decreased (by 87.2 and 88.4%, respectively, both p <  0.001), and affinity 
kinetics of these IgG were characterized by increased small and big Kd, respectively. 
MTX-treated rats displayed increased anxiety- but not depression-like behavior.
conclusion: MTX-induced anorexia, weight loss, and anxiety are accompanied by 
increased ghrelin production and by a decrease of ghrelin-reactive IgG levels and affinity 
binding properties. Such changes of ghrelin-reactive IgG may underlie their decreased 
ghrelin-transporting capacities compromising ghrelin orexigenic and anxiolytic effects 
and contributing to chemotherapy-induced loss of appetite.
Keywords: chemotherapy, intestinal inflammation, anorexia, ghrelin, autoantibodies
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inTrODUcTiOn
Cancer anorexia–cachexia syndrome is characterized by 
decreased food intake, weight loss, muscle tissue wasting, and 
psychological distress and is a major source of increased morbid-
ity and mortality in cancer patients (1). While cancer itself may 
cause anorexia (2, 3), anorexia induced by chemotherapy is an 
independent aggravating problem, which mechanisms need to be 
better clarified (4). Beside anorexia, anti-cancer chemotherapy is 
accompanied by other side effects including intestinal mucositis, 
negative nitrogen balance, diarrhea, nausea and vomiting, 
decreasing patient’s quality of life (5–10).
Ghrelin is a 28 amino acids, peptide hormone synthesized 
mainly in the gastric mucosa and released in circulation in 
its active acylated form (11). Acylated ghrelin binds to the 
growth hormone secretagogue receptor (GHSR) stimulating 
food intake via a hypothalamic circuitry (12), but is unstable 
and rapidly degraded by plasma enzymes resulting in des-acyl 
ghrelin (13). Although des-acyl ghrelin is the main form of 
the circulating peptide, it has no orexigenic effect (14). To this 
day, ghrelin is the only known peripheral factor stimulating 
appetite, but it is also a pleiotropic hormone with multiple 
functions (15), including modulating mood and emotion (16). 
Ghrelin was indeed shown to alleviate stress-induced anxiety 
and may also exert antidepressive-like effects when injected 
to rodents (17, 18).
Considering ghrelin’s effects on appetite, mood, and emotion, 
it has become an important target in the research of mechanisms 
and treatments of several conditions of anorexia–cachexia such 
as in cancer anorexia and anorexia nervosa (19–21). Few stud-
ies also explored the ghrelin status in chemotherapy-induced 
anorexia. As such, a decrease in plasma ghrelin was reported 
in cisplatin-treated rats and patients (22, 23), while adminis-
tration of an exogenous ghrelin stimulated food intake and 
minimized side effects (24). Moreover, an agonist of ghrelin 
improved appetite in 5-fluoruracil-treated mouse model of 
cancer-cachexia (25).
Methotrexate (MTX) is an anti-mitotic drug commonly used 
in cancer chemotherapy (26). We previously developed, in our 
laboratory, a rat model of MTX chemotherapy characterized by 
anorexia, cachexia, intestinal mucositis, impairment of absorp-
tion and digestive functions, alteration of the gut barrier, and 
diarrhea (27–30). While dehydration secondary to diarrhea was 
suggested to underlie the mechanisms of anorexia in this animal 
model of chemotherapy (31), possible involvement of the ghrelin 
system has not been studied.
In addition, we recently identified a role for ghrelin-reactive 
immunoglobulins (Ig) G, naturally present in plasma, in improv-
ing ghrelin’s stability by protecting it from degradation by plasma 
enzymes (32). Although MTX immunosuppressive properties 
were shown to decrease total IgG levels in rat plasma (33), its 
specific effect on ghrelin-reactive IgG was not studied.
Thus, in the present study, we investigated the effect of MTX 
on anxiety- and depression-like behavior, gastric preproghrelin 
mRNA-expressing cells, plasma concentrations of ghrelin as well 
as levels and affinity of ghrelin-reactive IgG in rats.
MaTerials anD MeThODs
animals
Male Sprague-Dawley rats (200–250 g) were obtained from Charles 
River Laboratories (France) and were housed in an air-conditioned 
room at 22°C with a 12:12  hours light–dark cycle (light period 
07:00–19:00 hours) in a fully equipped animal facility. Rats were 
kept in holding cages (three rats per cage) for 1 week before the 
experiment, in order to acclimatize them to the housing conditions. 
Standard pelleted rodent chow (RM1 diet, SDS, UK) was available 
ad libitum. Three days before MTX administration, the rats were 
transferred to metabolism cages (Tecniplast, Lyon, France) where 
they were fed with the same RM1 diet but in powdered form (SDS). 
Drinking water was always available ad libitum. Animal care and 
experimentation were in accordance with guidelines established 
by the National Institutes of Health, USA and complied with both 
French and European Community regulations (Official Journal of 
the European Community L 358, 18/12/1986).
MTX Model of anorexia–cachexia
Rats were divided into two groups (n = 12 in each) to achieve 
similar mean body weight: (i) MTX-treated and (ii) controls. 
A single dose of MTX (2.5  mg/kg, Teva Pharma, Courbevoie, 
France) dissolved in phosphate-buffered saline (PBS) was 
injected subcutaneously (S.C.) each day for three consecutive 
days (days 1–3). Control rats were injected S.C. with PBS. The 
dose and duration of MTX administration were selected based 
on our previous data showing typical response to MTX in rats 
characterized by anorexia and cachexia and loss of both lean and 
fat mass (31). Rats were gently handled daily during measure-
ments of their body weight.
Behavioral analyses
Behavioral tests, performed to evaluate the anxious- and depres-
sive-like behaviors in MTX-treated anorectic and in control rats, 
were carried out between 9.00 and 16.00 during the light period. 
A habituation to conditions of experimentation was performed 
the day preceding the experimental procedures. The rat’s sponta-
neous locomotion was recorded for 120 min, using a Versamax 
Animal Activity Monitor (AccuScan Instruments, Columbus, 
OH, USA). The rats were tested for their anxiety in an elevated 
plus-maze, which is commonly used and pharmacologically 
validated for anxiety testing in rodents (34). The plus-maze is 
elevated approximately 1 m from the floor, and the rat is given the 
choice of spending time in open, unprotected arms or enclosed, 
protected arms. The rats were tested for their depressive-like 
behavior in a forced-swim test. Rats were placed into a cylinder 
filled with tap water (25°C) to 1/3 of its volume. The total time 
of immobility during 15-min test procedure was registered. A rat 
was judged to be immobile when it floated in the water in an 
upright position and made only small adjustments movements 
to keep its head above water.
Tissue sampling
Rats were killed by decapitation between 10:00 and 11:00 a.m. at 
day 6 after beginning of MTX or PBS treatments. Trunk blood 
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was collected into tubes containing EDTA (1 mg/ml), aprotinin 
(500  U/ml), and 1N HCl (1:10  vol). Plasma was separated by 
centrifugation at 4°C and stored at −80°C until assayed. Plasma 
levels of ghrelin and des-acyl ghrelin were measured using enzy-
matic immunoassay kits from Mitsubishi Chemical Med Corp. 
(Tokyo, Japan), according to manufacturer’s instructions. The 
manufacturer specified the sensitivity of both kits at 2.5  fmol/
ml and absence of cross-reactivity between the active and des-
acylated forms of ghrelin in the corresponding detection assays. 
For in situ hybridization, the stomach tissue was frozen on dry 
ice, stored at −80°C, then cut in a cryostat (Leica Microsystems, 
Nanterre, France) to obtain 14-μm thick transversal sec-
tions collected on Superfrost glass slides (Thermo Scientific, 
Braunschweig, Germany).
In Situ hybridization
All solutions were made using diethylpyrocarbonate (DEPC, 
Sigma, St. Louis, MO, USA) treated water. Stomach sections were 
fixed with 4% paraformaldehyde in PBS, pH 7.5. After washing 
with PBS for 5 min, the sections were incubated with 0.5M HCl 
in DEPC water for 5 min and then washed in PBS twice for 3 min. 
Further, the sections were treated with 0.25% acetic anhydride 
in 0.1M triethanolamine, pH 8.0, for 20 min. The sections were 
washed in PBS twice for 3 min, and immersed in a graded ethanol 
series (70, 80, and 99.5%) for 2 min each. Finally, sections were 
dried for 30 min and then stored at −80°C.
RNA probes specific to preproghrelin mRNA (Accession 
number: NM_021669.2, National Center for Biotechnology 
Information, Bethesda, MD, USA) were prepared from rat 
stomach mRNA. The rat stomach extracted mRNA was 
reverse-transcribed to generate cDNA using the iScript select 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The cDNA 
was amplified using the following specific primers: ghrelin-F: 
5′-AGCACCAGAAAGCCCAGCAGAGAA-3′ and ghrelin-R: 
5′-TTGCAGAGGAGGCAGAAGCTGGAT-3′ (product size 
of 335  bp from position 121–455) (Invitrogen, Carlsbad, CA, 
USA). The PCR fragment was gel purified using QIAquick Gel 
extraction kit (Qiagen) and subcloned into PCR1II-TOPO vector 
(Invitrogen, Carlsbad, CA, USA). The sequence of cDNA probe 
was confirmed by nucleotide sequencing (KIGene, Stockholm, 
Sweden). The plasmids were linearized using restriction enzyme 
BAmHI and XbaI (Promega, Madison, WI, USA) and transcribed 
to generate sense and antisense RNA probes. In vitro transcription 
and labeling were carried out using SP6/T7 RNA polymerases 
(Ambion, Austin, TX, USA) and digoxigenin (DIG) RNA labeling 
mix (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer’s instructions. The transcripts were purified using 
NucAway Spin Columns (Ambion). Sense probes were used as 
negative controls.
Sections were prehybridized in a humidified chamber 
using 50% (v/v) deionized formamide, 0.1M Tris–HCl (pH 
7.6), 50 mM EDTA (pH 8.0), 40 mM NaCl, 1.25 mg/ml yeast 
tRNA (Roche), and 5× Denhardt’s solution for 4–6  h at 55°C 
followed by hybridization overnight (14–16  h) at 55°C. The 
labeled probes were diluted to a final concentration 0.8 ng/μl in 
solution containing 50% (v/v) deionized formamide, 0.3M NaCl, 
0.1 M DTT, 10% (vol/vol) dextran sulfate, and 1× Grundmix 
solution. Grundmix solution is made of 0.2M Tris–HCl (pH 7.6), 
5  mg/ml yeast tRNA (Roche), 1  mg/ml poly-A-RNA (Roche), 
10× Denhardt’s solution, and 10  mM EDTA (pH 8.0). After 
hybridization, sections were washed with constant stirring as 
follows: twice for 30 min in 1× SSC with 0.1% SDS at 55°C, 1 h 
in 50% (v/v) formamide/0.5× SSC at 55°C, 5 min in 1× SSC with 
0.1% SDS at 55°C, 30 min in 36 μg/ml RNase A diluted in RNase 
A buffer at 37°C, and twice for 10  min in 1× SSC with 0.1% 
SDS at 55°C. RNase A buffer contains 0.5M NaCl, 10 mM Tris 
(pH 8.0), and 0.5 mM EDTA. The sections were then incubated 
three times for 5 min in buffer 1 (100 mM Maleic acid, pH 7.5, 
150 mM NaCl, 0.02% tween 20), immersed in 1% blocking rea-
gent (Roche) diluted in buffer 1 for 20 min, and incubated with 
the alkaline phosphatase-conjugated anti-DIG antibody (Roche) 
diluted at 1:200 in buffer 1 with 1% blocking reagent at 4°C over-
night. The sections were then washed in buffer 1 for 5 min three 
times, in buffer 2 (100 mM Tris, pH 9.5, 100 mM NaCl, 0.05% 
tween 20) for 5 min, and in buffer 2 with 5 mM of tetramisole 
hydrochloride (Sigma) for 5 min. A chromagen solution made 
of 337 g/ml nitro-blue tetrazolium chloride (NBT) and 175 g/ml 
5-bromo-4-chloro-3′-indolyphosphate p-toluidine salt (BCIP) 
(Roche) in buffer 2 with 5  mM of tetramisole hydrochloride 
(Sigma) was made, and the sections were incubated for 24 h. The 
reaction was stopped with PBS. The sections were then washed 
with distilled water, mounted in a solution of PBS and glycerol 
(85%), and viewed under a light microscope (Axioskop, Zeiss, 
Germany). Pictures from the in  situ hybridization were taken 
with an objective 20×. Total number of preproghrelin mRNA-
positive cells was counted using Image J 1.45s software (National 
Institutes of Health, Bethesda, MD, USA) from five representa-
tive sections of each mouse. The square area including the gastric 
mucosa and sub-mucosa were delimited in Image J 1.45s in each 
picture, and the number of positive cells in the measured surface 
area was calculated.
ghrelin-reactive immunoglobulins
Ghrelin-reactive Ig levels were measured in rat plasma using 
an enzyme-linked immunosorbent assay (ELISA) accordingly 
to a published protocol (35). Briefly, 96-well plates (Nunc 
Immunoplate, Rochester, NY, USA) were coated with 2 mg/ml 
of rat ghrelin (Peptide institute, Inc., Japan) in 0.5M sodium 
carbonate (Na2CO3), 0.5M sodium bicarbonate (NaHCO3), pH 
9.6, and incubated for 72 h at 4°C. Plates were washed using PBS 
(0.05% Tween20, pH 7.4). Plasma was diluted 1:100 in either 
normal buffer (PBS, 0.02% sodium azide, pH 7.4) to measure 
free IgG or in dissociative 3M NaCl, 1.5M glycine (pH 8.9) 
buffer, to measure total ghrelin IgG levels. After incubation at 
4°C overnight, plates were washed and incubated for 3 h with 
alkaline phosphatase-conjugated secondary antibody (anti-rat 
IgG; Jackson ImmunoResearch, West Grove, PA, USA). The 
reaction was developed for 40  min with 150 μl p-nitrophenyl 
phosphatase substrate solution (Sigma, St Louis, MO, USA) at 
1 mg/ml in 0.1M Tris–HCl, 0.1M NaCl, 5 mM magnesium chlo-
ride hexahydrate (MgCl2⋅6H20), pH 9.5. About 100 μl sodium 
hydroxyde (NaOH) (2M) was added to stop the reaction and 
optical density (OD) was measured at 405  nm in an ELISA 
plate reader.
FigUre 1 | Body weight (a), daily food intake (B), and water intake (c) of MTX-treated and PBs-treated control rats (both, n = 10). Ratios of daily water 
to food intakes (D). Two-way RM ANOVA with Bonferroni post-tests ***p < 0.001, effects of time p < 0.0001 (mean ± SEM).
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igg Purification
Plasma samples were purified using a Melon Gel kit according 
to the manufacturer instruction (Thermo Fisher Scientific, 
Rockford, IL, USA). After the purification, IgG was frozen at 
−30°C and lyophilized overnight. Then, they were suspended 
in the HBS-EP buffer (GE Healthcare). The IgG concentration 
of each sample was determined with a Nanodrop®, and HBS-EP 
buffer was used as a blank.
affinity Kinetics analysis
Affinity kinetics of mice IgG for ghrelin and des-acyl-ghrelin was 
determined by surface plasmon resonance (SPR) on a BIAcore 
1000 instrument (GE Healthcare) according to a published 
protocol (36). In brief, rat ghrelin (Peptide institute) was diluted 
at 0.5  mg/ml in 10  mM sodium acetate buffer (pH 5.0) (GE 
Healthcare) and was covalently coupled on the sensor chip CM5 
(GE Healthcare), using the amine coupling kit (GE Healthcare). 
All the measurements were done on the same sensor chip. For the 
affinity kinetic analysis, a multi-cycle method was run with five 
serial dilutions at 1/2 of each IgG sample: 1680–105 nM plus a 
duplicate of a blank (buffer only) at the beginning and at the end 
of the kinetic. During each cycle, the flow speed was 30 μl/min. 
About 60 μl of each sample dilution were injected correspond to 
2-min period followed by 5 min of dissociation. Then, between 
injections of each dilution, the binding surface was regenerated 
with 10 mM NaOH resulting in the return of the sensorgram to 
the same baseline. The affinity kinetic data were analysed using 
BiaEvaluation 4.1.1 programme (GE Healthcare). For fitting 
kinetic data, the Langmuir’s 1:1 model was used, and the sample 
values were corrected by subtracting the blank values resulting 
from the injection of HBS-EP buffer.
statistical analysis
Group differences were statistically analyzed using GraphPad 
Prism 5.02 (GraphPad software Inc., San Diego, CA, USA). 
Differences in daily food intake, body weight, and water intake 
were analyzed by a two-way repeated measurements (RM) 
ANOVA taking in account effects of time and treatment followed 
by the Bonferroni post-tests. Individual groups were compared 
using the Student’s t-test or Mann–Whitney test according to 
the Kolmogorov–Smirnov (KS) normality test, and p < 0.05 was 
considered as significant.
resUlTs
Food intake, Body Weight, and Water 
intake
Methotrexate-treated rats displayed significant body weight loss 
(Figure 1A) and decreased food intake (Figure 1B) starting from 
day 3 after the first MTX injection. Water intake was reduced 
from day 4 (Figure 1C). Food intake was completely inhibited in 
MTX-treated rats at days 5 and 6 when they lost 33.7% of body 
weight as compared to control rats. The ratios of water to food 
intake were increased in anorectic MTX-treated rats (Figure 1D).
FigUre 2 | representative microphotographs of preproghrelin mrna-expressing cells in the stomach of PBs-treated control rats (n = 10) (a) and 
MTX-treated rats (n = 7) (B) revealed by in situ hybridization with Dig-labeled preproghrelin anti-sense riboprobes. (c) Quantification of the number of 
preproghrelin mRNA-positive cells in the gastric mucosal and submucosal layers of control and MTX-treated rats. Student’s t-test, ***p < 0.001, KS test p > 0.1 
both (mean ± SEM). Scale bar, 100 μm.
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Preproghrelin mrna-Producing cells
In situ hybridization revealed the presence of preproghrelin 
mRNA-expressing cells in the mucosal and sub-mucosal 
layers of the gastric wall of all control and MTX-treated rats 
(Figures 2A,B). The negative control did not show any positive 
cells (not shown). The number of preproghrelin mRNA-producing 
cells was increased by 51.3% in MTX-treated rats as compared to 
controls (Figure 2C). The gastric mucosa in MTX-treated rats did 
not show signs of atrophy.
Plasma levels of ghrelin
Plasma levels of ghrelin and des-acyl ghrelin were robustly 
increased in MTX-treated vs. control rats (Figures 3A,B) while 
their ratios remained similar (Figure 3C).
ghrelin-reactive igg
Methotrexate-treated rats showed decreased plasma levels of both 
free and total acyl ghrelin-reactive IgG (Figures 4A,B) and free 
and total des-acyl ghrelin-reactive IgG (Figures 4D,E). The ratios 
of free to total IgG reactive with both ghrelin and des-acyl-ghrelin 
were increased in MTX-treated rats (Figures 4C,F).
affinity Kinetics of igg for ghrelin
The analysis of affinity kinetics using SPR revealed increased 
dissociation rates (small Kd) of IgG for ghrelin in MTX-treated 
rats (Figure  5B), who also displayed increased dissociation 
equilibrium constants (big KD) of their IgG for des-acyl-ghrelin 
(Figure 5F). Other parameters of affinity kinetics were not sig-
nificantly different among the groups (Figures 5A,C,D,E).
anxious- and Depressive-like Behavior
Locomotor activity, including time of movement and crossed 
distance, was unchanged between MTX and control groups 
(Table 1). The number of entries in both open and closed arms 
in the elevated plus-maze was decreased in the MTX-treated rats 
(Table 1). The time spent in both open and closed areas was not 
significantly different between the groups, although MTX-treated 
rats tended to spend less time in open arms. There was no either 
significant differences between MTX and control groups in the 
immobility time of the forced-swim test (Table 1).
DiscUssiOn
In this study, we analyzed the effects of MTX on preproghrelin 
mRNA-expressing cells and plasma levels of ghrelin and ghrelin-
reactive IgG in a rat model of chemotherapy-induced anorexia. 
We found that the number of preproghrelin mRNA-producing 
cells was increased in rats treated with MTX, accompanied by 
increased plasma concentrations of both ghrelin and des-acyl-
ghrelin. In contrast, plasma levels of ghrelin- and des-acyl-
ghrelin-reactive IgG were strongly decreased in MTX-treated 
anorectic rats and further displayed altered properties of their 
affinity kinetics, indicative of reduced biding of ghrelin and 
des-acyl-ghrelin. To our knowledge, this is the first report on the 
effect of MTX on the ghrelinergic system. Moreover, we showed 
that MTX-treated rats displayed increased anxiety- but not 
depression-like behavior.
First of all, our data revealed that MTX-induced anorexia is not 
due to a decreased ghrelin production by the stomach, which could 
be expected because of MTX-induced mucositis. In contrast, we 
found that the number of preproghrelin mRNA-expressing cells 
was increased in MTX-treated rats supporting the preservation of 
a normal feedback control from the negative energy balance that 
upregulates ghrelin’s gene expression (37). Our previous work 
using the same rat model of MTX chemotherapy supported a key 
role of dehydration in appearance of anorexia and weight loss (31). 
The underlying pathophysiological process included intestinal 
mucositis-induced diarrhea, fluids loss, and activation of brain 
structures signaling dehydration including oxytocin neurons in 
the hypothalamic paraventricular nucleus (31). Such oxytocin 
neurons display important anorexigenic activity counteracting 
the ghrelin-activated brain hunger pathway (38, 39). Increased 
water to food intake ratios during anorexia in MTX-treated rats 
suggest that decreased food intake was not secondary to inhibited 
drinking. Although the ghrelin production does not appear to 
cause anorexia in the MTX rat model, its altered signaling may 
still contribute to the insufficient orexigenic effects of ghrelin to 
reduce the negative energy balance and to counteract other side 
effects of chemotherapy.
Negative energy balance is, indeed, typically accompanied by 
upregulation of the ghrelin gene expression and its plasma levels. 
FigUre 4 | Plasma concentrations of free (a,D) and total (B,e) igg reactive with ghrelin (a,B) and des-acyl ghrelin (D,e) in MTX-treated (n = 10) and 
PBs-treated control rats (n = 10). Mann–Whitney or Student’s t-test (a,e) according to the KS normality tests, *p < 0.05, **p < 0.01, ***p < 0.001. KS tests, (a) 
p > 0.1 and p = 0.08, (B) p > 0.1 and p = 0.03, (c) p > 0.1 and p = 0.003, (D) p > 0.1 and p = 0.005, (e) p > 0.1 and p = 0.1, (F) p > 0.1 and p = 0.006 
(mean ± SEM).
FigUre 3 | Plasma concentrations of ghrelin (a), des-acyl ghrelin (B), and their ratios (c) in PBs-treated controls (n = 8) and MTX-treated (n = 10). 
*p < 0.05, Mann–Whitney test, KS test p = 0.03 and p > 0.1 and **p < 0.01 Student’s t-test, KS test p > 0.1 both (mean ± SEM).
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For instance, patients with anorexia nervosa display elevated 
ghrelin concentrations, associated with lower body mass index 
and fat mass (40–43). Chronic food restriction in rodents is also 
accompanied by increased plasma ghrelin (44–47). Moreover, we 
have recently showed that the number of preproghrelin mRNA-
expressing cells in the stomach of mice with activity-based 
anorexia and chronic food restriction was increased proportion-
ally to their body weight loss (48). Thus, the present data of the 
increased number of ghrelin-expressing cells and ghrelin levels in 
plasma after MTX treatment are in agreement with the results in 
both humans and rodents characterized by negative energy bal-
ance. However, our results are contrasting with a study showing 
an impaired ghrelin production in cancer chemotherapy-induced 
anorexia using cisplatin (22, 23). It suggests that ghrelin system 
might be differentially affected by different types of chemo-
therapy, which may involve impaired secretion by the gastric 
A/X-like-type cells, decreased production/activity of the ghrelin 
O-acyltransferase, enzyme responsible for the posttranscriptional 
acylation of ghrelin precursor (49), or an increased degradation 
of total and acylated ghrelin by plasmatic enzymes such as 
lysophospholipase 1 (50).
Considering the immunosuppressive properties of MTX, we 
tested if MTX alters production of ghrelin-reactive IgG. Both free 
and total levels of IgG reacting with either acylated or des-acylated 
forms of ghrelin were strongly decreased under the effect of MTX. 
An impairment of ghrelin-reactive IgG production can be due to 
TaBle 1 | Behavioral tests results.
PBs-controls (mean ± seM) MTX-treated (mean ± seM) statistical test p-values
Locomotor activity Time (s) 466.0 ± 125.0 449.2 ± 138.4 Student’s t-test 0.46
Distance (cm) 5218 ± 1484 4661 ± 1519 Student’s t-test 0.4
Forced-swim test Immobility time (s) 3.2 ± 0.15 3.23 ± 0.09 Student’s t-test 0.43
Elevated plus-maze Total distance (cm) 1486 ± 114.7 1728 ± 209.3 Mann–Whitney 0.14
Closed arms Distance (cm) 1273 ± 88.08 1498 ± 194.7 Student’s t-test 0.13
Entries 23.38 ± 3.21 15.50 ± 2.922 Mann–Whitney 0.016
Time (s) 198.6 ± 8.57 212.9 ± 12.37 Student’s t-test 0.18
Open arms + central area Distance (cm) 213.0 ± 24.30 230.0 ± 63.59 Student’s t-test 0.39
Entries 31.88 ± 2.95 18.00 ± 3.31 Mann–Whitney 0.007
  Time (s) 98.17 ± 8.84 73.11 ± 12.78 Mann–Whitney 0.05
Results of the locomotor activity test (time and distance), the forced-swim test (immobility time), and the elevated plus-maze test (distance, entries and time spent in closed or open 
arms) in PBS-treated controls (n = 8) and MTX-treated rats (n = 8). Student’s or Mann–Whitney tests were used according the Kolmogorov–Smirnov normality test, and p < 0.05 
was considered as significant (boldface values).
FigUre 5 | sPr affinity kinetics analysis of ghrelin- (a–c) and des-acyl ghrelin (D–F)-reactive igg in MTX-treated (n = 9) and PBs-treated control 
rats (n = 7). The affinity kinetic parameters are: the association rates (small ka) (a,D), the dissociation rates (small kd) (B,e) and the dissociation equilibrium 
constants (KD) (c,F). Student’s t-test (B) or Mann–Whitney test according to the KS normality tests, *p < 0.05. KS tests, (B), p > 0.1 both and (F), p = 0.02 and 
p > 0.1 (mean ± SEM).
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MTX-induced mucositis affecting gut lymphoid tissue and other 
lymphoid organs but is not likely to be a result of food restriction 
per se since we previously showed that total plasma IgG concen-
trations were increased in rats pair-fed with rats displaying MTX-
induced anorexia (33). Ghrelin-reactive IgG protect ghrelin from 
degradation and enhance its orexigenic effect depending on IgG 
affinity for ghrelin, which is slightly increased in obese humans, 
mice, and rats (32, 51). It suggests that ghrelin can be transported 
by plasmatic IgG toward its receptors and that increased, but still 
remaining in the micromolar range, affinity of IgG is associated 
with its better transportation. Inversely, a decrease in affinity of 
IgG for ghrelin may reduce such transportation ability. Therefore, 
low levels of ghrelin-reactive IgG and changes of their affinity 
kinetics showing increased dissociation of ghrelin, may diminish 
ghrelin’s stability and signaling. Increased ratios of free to total 
ghrelin-reactive IgG may also reflect their decreased ability to 
form immune complexes with ghrelin. Similarly to such changes 
in MTX anorectic rats, previous studies in patients with anorexia 
nervosa also found low plasma levels of ghrelin-reactive IgG, 
which were increased after refeeding (52) and were also charac-
terized by increased dissociation rates (32). Further experiments 
will be required to test if administration of ghrelin-reactive IgG 
may enhance ghrelin’s orexigenic effects to counteract anorexia, 
e.g., during cancer chemotherapy. Although our recent study 
using such experimental approach in mice with activity-based 
anorexia did not show superior results as compared to the use of 
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ghrelin alone, a short-time access to food in this animal model of 
anorexia was a limitation to fully evaluate a therapeutic potential 
of increasing ghrelin’s stability using IgG (47).
Distress, anxiety, and depression are often observed in cancer 
patients (53) and can be aggravated by chemotherapy (54, 55), 
highlighting high psychological and psychiatric co-morbidity. 
Although the mechanisms of these diseases are not fully under-
stood, there is growing evidence of the role of the gut–brain 
axis, including gut microbiota-derived signals acting directly 
or via inflammatory mediators on the nervous system (56–58). 
Cancer chemotherapy, primary aimed at inhibiting tumor cell 
proliferation, also destroys gut mucosal layer composed of 
continuously renewed cells, resulting in increased gut barrier 
permeability such as in our MTX chemotherapy model (28). 
It is hence likely that MTX-induced damage of the gut barrier 
may be accompanied by increased anxiety- and depression-like 
behavior in rats. In this study, we found that MTX did not 
induce a depressive-like behavior in rats in the forced-swim 
test, but decreased the number of entries in both open and 
closed arms in the elevated plus-maze. Considering their 
normal locomotor pre-test activity, these changes indicate that 
MTX may increase anxiety distinctly from the despair-related 
depressive-like symptoms of the forced-swim test. Because 
ghrelin plays a role in the stress-induced emotional regulation 
(16), the impairment of ghrelin signaling could also contribute 
to the elevated anxiety in MTX-treated rats. Changes of ghrelin-
reactive IgG, which were inhibited by MTX, may potentially 
contribute to the increased anxiety. In fact, we have recently 
found that serum levels of ghrelin-reactive IgM and IgG corre-
late with anxiety and the stress-response in a general population 
of adolescents (59). Although these associations were weak and 
probably reflected some physiological variations of anxiety 
in healthy adolescents with normal levels of ghrelin-reactive 
autoantibodies, a dramatic decrease of ghrelin-reactive IgG in 
MTX-treated rats may potentially diminish ghrelin’s protective 
role in stress-induced anxiety.
cOnclUsiOn
In conclusion, this study reveals that MTX chemotherapy-
induced anorexia–cachexia in rats is accompanied by increased 
ghrelin production but lower levels and binding affinity kinetics 
of IgG that transport ghrelin and protect it from degradation. 
Such changes of ghrelin-transporting IgG may compromise 
ghrelin signaling potentially contributing to anorexia, weight loss 
and anxiety in MTX chemotherapy-induced anorexia–cachexia.
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